Conjugation to poly(amidoamine) dendrimers and pulmonary delivery reduce cardiac accumulation and enhance antitumor activity of doxorubicin in lung metastasis

Molecular Pharmaceutics

Volumn 13, Issue 7, 2016, Pages 2363-2375

  Zhong, Qian ^a   Bielski, Elizabeth R ^a   Rodrigues, Leonan S ^a   Brown, Matthew R ^a   Reineke, Joshua J ^b   Da Rocha, Sandro R P ^a,c,d  

^a Wayne State University   (United States)

^b SOUTH DAKOTA STATE UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Virginia Commonwealth University   (United States)

Author keywords

cardiac toxicity; controlled intracellular release; doxorubicin; lung cancer; Polyamidoamine dendrimer; pulmonary delivery

Indexed keywords

CARBONYL DERIVATIVE; DENDRIMER; DOXORUBICIN; HYDRAZIDE; NANOCARRIER; POLYAMIDOAMINE; PAMAM STARBURST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEACHING; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; DIALYSIS MEMBRANE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; ENDOCYTOSIS; HYDRODYNAMICS; HYDROPHOBICITY; INTERNALIZATION; LUNG ALVEOLUS MACROPHAGE; LUNG METASTASIS; LUNG NODULE; LYSOSOME; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MELANOMA CELL LINE; MOUSE; MTT ASSAY; NONHUMAN; PHAGOCYTOSIS; PINOCYTOSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SURFACE CHARGE; SUSTAINED DRUG RELEASE; SYSTEMIC CIRCULATION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DENDRIMERS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; LUNG; LUNG NEOPLASMS; MALE; MELANOMA; MICE; MICE, INBRED C57BL;

EID: 84978997914     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00126     Document Type: Article

References (79)

1. Kochanek, K. D.; Murphy, S. L.; Xu, J.; Arias, E. Mortality in the United States, 2013; Centers for Disease Control and Prevetion: 2014; p 8.
2. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013 Ca-Cancer J. Clin. 2013, 63 (1) 11-30 10.3322/caac.21166
3. Wada, H.; Hitomi, S.; Teramatsu, T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery J. Clin. Oncol. 1996, 14 (4) 1048-1054
4. Albain, K. S.; Swann, R. S.; Rusch, V. W.; Turrisi, A. T.; Shepherd, F. A.; Smith, C.; Chen, Y.; Livingston, R. B.; Feins, R. H.; Gandara, D. R. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial Lancet 2009, 374 (9687) 379-386 10.1016/S0140-6736(09)60737-6
5. Gupta, G. P.; Massagué, J. Cancer metastasis: building a framework Cell 2006, 127 (4) 679-695 10.1016/j.cell.2006.11.001
6. Nguyen, D. X.; Bos, P. D.; Massagué, J. Metastasis: from dissemination to organ-specific colonization Nat. Rev. Cancer 2009, 9 (4) 274-284 10.1038/nrc2622
7. Garbuzenko, O. B.; Saad, M.; Pozharov, V. P.; Reuhl, K. R.; Mainelis, G.; Minko, T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (23) 10737-10742 10.1073/pnas.1004604107
8. Zhu, S.; Hong, M.; Tang, G.; Qian, L.; Lin, J.; Jiang, Y.; Pei, Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style Biomaterials 2010, 31 (6) 1360-1371 10.1016/j.biomaterials.2009.10.044
9. Cheng, C.; Haouala, A.; Krueger, T.; Mithieux, F.; Perentes, J. Y.; Peters, S.; Decosterd, L. A.; Ris, H.-B. Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin Interact. Cardiovasc. Thorac. Surg. 2009, 8 (6) 635-638 10.1510/icvts.2008.194720
10. Broxterman, H. J.; Versantvoort, C. H.; Linn, S. C. Multidrug resistance in lung cancer. In Lung Cancer; Springer: 1995; pp 193-222.
11. Blum, R. H.; Carter, S. K. Adriamycin: a new anticancer drug with significant clinical activity Ann. Intern. Med. 1974, 80 (2) 249-259 10.7326/0003-4819-80-2-249
12. Koukourakis, M.; Koukouraki, S.; Giatromanolaki, A.; Archimandritis, S.; Skarlatos, J.; Beroukas, K.; Bizakis, J.; Retalis, G.; Karkavitsas, N.; Helidonis, E. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer J. Clin. Oncol. 1999, 17 (11) 3512-3521
13. Otterson, G. A.; Villalona-Calero, M. A.; Hicks, W.; Pan, X.; Ellerton, J. A.; Gettinger, S. N.; Murren, J. R. Phase I/II Study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer Clin. Cancer Res. 2010, 16 (8) 2466-2473 10.1158/1078-0432.CCR-09-3015
14. Zhong, Q.; da Rocha, S. R. P. Poly(amidoamine) dendrimer-doxorubicin conjugates: in vitro characteristics and pseudosolution formulation in pressurized metered-dose inhalers Mol. Pharmaceutics 2016, 13 (3) 1058-1072 10.1021/acs.molpharmaceut.5b00876
15. Thorn, C. F.; Oshiro, C.; Marsh, S.; Hernandez-Boussard, T.; McLeod, H.; Klein, T. E.; Altman, R. B. Doxorubicin pathways: pharmacodynamics and adverse effects Pharmacogenet. Genomics 2011, 21 (7) 440 10.1097/FPC.0b013e32833ffb56
16. Hagane, K.; Akera, T.; Berlin, J. Doxorubicin: mechanism of cardiodepressant actions in guinea pigs J. Pharmacol. Exp. Ther. 1988, 246 (2) 655-661
17. Chatterjee, K.; Zhang, J.; Honbo, N.; Karliner, J. S. Doxorubicin cardiomyopathy Cardiology 2010, 115 (2) 155-162 10.1159/000265166
18. Roa, W. H.; Azarmi, S.; Al-Hallak, M. K.; Finlay, W. H.; Magliocco, A. M.; Löbenberg, R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model J. Controlled Release 2011, 150 (1) 49-55 10.1016/j.jconrel.2010.10.035
19. Kim, I.; Byeon, H. J.; Kim, T. H.; Lee, E. S.; Oh, K. T.; Shin, B. S.; Lee, K. C.; Youn, Y. S. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer Biomaterials 2012, 33 (22) 5574-5583 10.1016/j.biomaterials.2012.04.018
20. Kaminskas, L. M.; McLeod, V. M.; Ryan, G. M.; Kelly, B. D.; Haynes, J. M.; Williamson, M.; Thienthong, N.; Owen, D. J.; Porter, C. J. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy J. Controlled Release 2014, 183, 18-26 10.1016/j.jconrel.2014.03.012
21. Xu, C.; Wang, P.; Zhang, J.; Tian, H.; Park, K.; Chen, X. Pulmonary codelivery of doxorubicin and siRNA by pH-sensitive nanoparticles for therapy of metastatic lung cancer Small 2015, 11 (34) 4321-4333 10.1002/smll.201501034
22. Menjoge, A. R.; Kannan, R. M.; Tomalia, D. A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications Drug Discovery Today 2010, 15 (5) 171-185 10.1016/j.drudis.2010.01.009
23. Tomalia, D. A.; Naylor, A. M.; Goddard, W. A. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter Angew. Chem., Int. Ed. Engl. 1990, 29 (2) 138-175 10.1002/anie.199001381
24. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity Adv. Drug Delivery Rev. 2005, 57 (15) 2215-2237 10.1016/j.addr.2005.09.019
25. Bharatwaj, B.; Mohammad, A. K.; Dimovski, R.; Cassio, F. L.; Bazito, R. C.; Conti, D.; Fu, Q.; Reineke, J.; da Rocha, S. R. Dendrimer nanocarriers for transport modulation across models of the pulmonary epithelium Mol. Pharmaceutics 2015, 12 (3) 826-838 10.1021/mp500662z
26. Zhong, Q.; Merkel, O. M.; Reineke, J. J.; da Rocha, S. R. P. Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution Mol. Pharmaceutics 2016, 13, 1866 10.1021/acs.molpharmaceut.6b00036
27. Bielski, E. R.; Zhong, Q.; Brown, M.; da Rocha, S. R. P. Effect of the Conjugation Density of Triphenylphosphonium Cation on the Mitochondrial Targeting of Poly(amidoamine) Dendrimers Mol. Pharmaceutics 2015, 12 (8) 3043-3053 10.1021/acs.molpharmaceut.5b00320
28. Kitchens, K. M.; Foraker, A. B.; Kolhatkar, R. B.; Swaan, P. W.; Ghandehari, H. Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells Pharm. Res. 2007, 24 (11) 2138-2145 10.1007/s11095-007-9415-0
29. Dobrovolskaia, M. A.; Patri, A. K.; Simak, J.; Hall, J. B.; Semberova, J.; De Paoli Lacerda, S. H.; McNeil, S. E. Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro Mol. Pharmaceutics 2012, 9 (3) 382-393 10.1021/mp200463e
30. Cheng, Y.; Xu, T. The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs Eur. J. Med. Chem. 2008, 43 (11) 2291-2297 10.1016/j.ejmech.2007.12.021
31. Lai, P.-S.; Lou, P.-J.; Peng, C.-L.; Pai, C.-L.; Yen, W.-N.; Huang, M.-Y.; Young, T.-H.; Shieh, M.-J. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy J. Controlled Release 2007, 122 (1) 39-46 10.1016/j.jconrel.2007.06.012
32. Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuli-responsive nanocarriers for drug and gene delivery J. Controlled Release 2008, 126 (3) 187-204 10.1016/j.jconrel.2007.12.017
33. Rao, G.; Tinkle, S.; Weissman, D.; Antonini, J.; Kashon, M.; Salmen, R.; Battelli, L.; Willard, P.; Hubbs, A.; Hoover, M. Efficacy of a technique for exposing the mouse lung to particles aspirated from the pharynx J. Toxicol. Environ. Health, Part A 2003, 66 (15-16) 1441-1452 10.1080/15287390306417
34. Mohammad, A. K.; Amayreh, L. K.; Mazzara, J. M.; Reineke, J. J. Rapid lymph accumulation of polystyrene nanoparticles following pulmonary administration Pharm. Res. 2013, 30 (2) 424-434 10.1007/s11095-012-0884-4
35. Medina, S. H.; El-Sayed, M. E. Dendrimers as carriers for delivery of chemotherapeutic agents Chem. Rev. 2009, 109 (7) 3141-3157 10.1021/cr900174j
36. Etrych, T.; Jelínková, M.; Říhová, B.; Ulbrich, K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties J. Controlled Release 2001, 73 (1) 89-102 10.1016/S0168-3659(01)00281-4
37. Wu, A. M.; Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 2005, 23 (9) 1137-1146 10.1038/nbt1141
38. Lu, C.; Zhong, W. Synthesis of propargyl-terminated heterobifunctional poly (ethylene glycol) Polymers 2010, 2 (4) 407-417 10.3390/polym2040407
39. King, H. D.; Yurgaitis, D.; Willner, D.; Firestone, R. A.; Yang, M. B.; Lasch, S. J.; Hellström, K. E.; Trail, P. A. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates Bioconjugate Chem. 1999, 10 (2) 279-288 10.1021/bc980100i
40. Kaminskas, L. M.; Boyd, B. J.; Porter, C. J. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties Nanomedicine 2011, 6 (6) 1063-1084 10.2217/nnm.11.67
41. Albanese, A.; Tang, P. S.; Chan, W. C. The effect of nanoparticle size, shape, and surface chemistry on biological systems Annu. Rev. Biomed. Eng. 2012, 14, 1-16 10.1146/annurev-bioeng-071811-150124
42. Rlhová, B.; Etrych, T.; Pechar, M.; Jellnková, M.; Štastný, M.; Hovorka, O.; Kovář, M.; Ulbrich, K. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes J. Controlled Release 2001, 74 (1) 225-232 10.1016/S0168-3659(01)00320-0
43. Tokudome, T.; Mizushige, K.; Noma, T.; Manabe, K.; Murakami, K.; Tsuji, T.; Nozaki, S.; Tomohiro, A.; Matsuo, H. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry J. Cardiovasc. Pharmacol. 2000, 36 (3) 361-368 10.1097/00005344-200009000-00012
44. Cardinale, D.; Colombo, A.; Sandri, M. T.; Lamantia, G.; Colombo, N.; Civelli, M.; Martinelli, G.; Veglia, F.; Fiorentini, C.; Cipolla, C. M. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 2006, 114 (23) 2474-2481 10.1161/CIRCULATIONAHA.106.635144
45. Vejpongsa, P.; Yeh, E. T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities J. Am. Coll. Cardiol. 2014, 64 (9) 938-945 10.1016/j.jacc.2014.06.1167
46. Speelmans, G.; Staffhorst, R. W.; de Kruijff, B.; de Wolf, F. A. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflet of the plasma membrane Biochemistry 1994, 33 (46) 13761-13768 10.1021/bi00250a029
47. De Duve, C.; De Barsy, T.; Poole, B.; Trouet, A.; Tulkens, P.; Van Hoof, F. Lysosomotropic agents Biochem. Pharmacol. 1974, 23 (18) 2495-2531 10.1016/0006-2952(74)90174-9
48. Malik, N.; Evagorou, E. G.; Duncan, R. Dendrimer-platinate: a novel approach to cancer chemotherapy Anti-Cancer Drugs 1999, 10 (8) 767-776 10.1097/00001813-199909000-00010
49. Frezard, F.; Garnier-Suillerot, A. DNA-containing liposomes as a model for the study of cell membrane permeation by anthracycline derivatives Biochemistry 1991, 30 (20) 5038-5043 10.1021/bi00234a028
50. Albertazzi, L.; Serresi, M.; Albanese, A.; Beltram, F. Dendrimer internalization and intracellular trafficking in living cells Mol. Pharmaceutics 2010, 7 (3) 680-688 10.1021/mp9002464
51. Kitchens, K. M.; Kolhatkar, R. B.; Swaan, P. W.; Ghandehari, H. Endocytosis inhibitors prevent poly (amidoamine) dendrimer internalization and permeability across Caco-2 cells Mol. Pharmaceutics 2008, 5 (2) 364-369 10.1021/mp700089s
52. Seib, F. P.; Jones, A. T.; Duncan, R. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells J. Controlled Release 2007, 117 (3) 291-300 10.1016/j.jconrel.2006.10.020
53. Sahay, G.; Alakhova, D. Y.; Kabanov, A. V. Endocytosis of nanomedicines J. Controlled Release 2010, 145 (3) 182-195 10.1016/j.jconrel.2010.01.036
54. Minko, T.; Kopečková, P.; Pozharov, V.; Kopeček, J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line J. Controlled Release 1998, 54 (2) 223-233 10.1016/S0168-3659(98)00009-1
55. Dufès, C.; Uchegbu, I. F.; Schätzlein, A. G. Dendrimers in gene delivery Adv. Drug Delivery Rev. 2005, 57 (15) 2177-2202 10.1016/j.addr.2005.09.017
56. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery Cell. Mol. Life Sci. 2009, 66 (17) 2873-2896 10.1007/s00018-009-0053-z
57. Perumal, O. P.; Inapagolla, R.; Kannan, S.; Kannan, R. M. The effect of surface functionality on cellular trafficking of dendrimers Biomaterials 2008, 29 (24) 3469-3476 10.1016/j.biomaterials.2008.04.038
58. Goldberg, D. S.; Ghandehari, H.; Swaan, P. W. Cellular entry of G3. 5 poly (amido amine) dendrimers by clathrin-and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia Pharm. Res. 2010, 27 (8) 1547-1557 10.1007/s11095-010-0153-3
59. Alfonso, A.; Payne, G. S.; Donaldson, J.; Segev, N. Trafficking Inside Cells: Pathways, Mechanisms and Regulation; Springer Science & Business Media: 2010.
60. Lakatos, H. F.; Burgess, H. A.; Thatcher, T. H.; Redonnet, M. R.; Hernady, E.; Williams, J. P.; Sime, P. J. Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation Exp. Lung Res. 2006, 32 (5) 181-199 10.1080/01902140600817465
61. Driscoll, K. E.; Costa, D. L.; Hatch, G.; Henderson, R.; Oberdorster, G.; Salem, H.; Schlesinger, R. B. Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations Toxicol. Sci. 2000, 55 (1) 24-35 10.1093/toxsci/55.1.24
62. Xu, Z.; Ramishetti, S.; Tseng, Y.-C.; Guo, S.; Wang, Y.; Huang, L. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis J. Controlled Release 2013, 172 (1) 259-265 10.1016/j.jconrel.2013.08.021
63. Hu, Y.-L.; Huang, B.; Zhang, T.-Y.; Miao, P.-H.; Tang, G.-P.; Tabata, Y.; Gao, J.-Q. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection Mol. Pharmaceutics 2012, 9 (9) 2698-2709 10.1021/mp300254s
64. Ryan, G. M.; Kaminskas, L. M.; Kelly, B. D.; Owen, D. J.; McIntosh, M. P.; Porter, C. J. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent Mol. Pharmaceutics 2013, 10 (8) 2986-2995 10.1021/mp400091n
65. Liu, H.; Irvine, D. J. Guiding principles in the design of molecular bioconjugates for vaccine applications Bioconjugate Chem. 2015, 26, 791 10.1021/acs.bioconjchem.5b00103
66. Prabhakar, U.; Maeda, H.; Jain, R. K.; Sevick-Muraca, E. M.; Zamboni, W.; Farokhzad, O. C.; Barry, S. T.; Gabizon, A.; Grodzinski, P.; Blakey, D. C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res. 2013, 73 (8) 2412-2417 10.1158/0008-5472.CAN-12-4561
67. Semmler-Behnke, M.; Takenaka, S.; Fertsch, S.; Wenk, A.; Seitz, J.; Mayer, P.; Oberdörster, G.; Kreyling, W. G. Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium Environ. Health Perspect. 2007, 115, 728-733 10.1289/ehp.9685
68. Harmsen, A. G.; Muggenburg, B. A.; Snipes, M. B.; Bice, D. E. The role of macrophages in particle translocation from lungs to lymph nodes Science 1985, 230 (4731) 1277-1280 10.1126/science.4071052
69. Lai, S. K.; Wang, Y.-Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues Adv. Drug Delivery Rev. 2009, 61 (2) 158-171 10.1016/j.addr.2008.11.002
70. Choi, H. S.; Ashitate, Y.; Lee, J. H.; Kim, S. H.; Matsui, A.; Insin, N.; Bawendi, M. G.; Semmler-Behnke, M.; Frangioni, J. V.; Tsuda, A. Rapid translocation of nanoparticles from the lung airspaces to the body Nat. Biotechnol. 2010, 28 (12) 1300-1303 10.1038/nbt.1696
71. Singal, P. K.; Iliskovic, N. Doxorubicin-induced cardiomyopathy N. Engl. J. Med. 1998, 339 (13) 900-905 10.1056/NEJM199809243391307
72. Chambers, A. F.; Groom, A. C.; MacDonald, I. C. Metastasis: dissemination and growth of cancer cells in metastatic sites Nat. Rev. Cancer 2002, 2 (8) 563-572 10.1038/nrc865
73. Xiao, K.; Li, Y.; Luo, J.; Lee, J. S.; Xiao, W.; Gonik, A. M.; Agarwal, R.; Lam, K. S. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles Biomaterials 2011, 32 (13) 3435-3446 10.1016/j.biomaterials.2011.01.021
74. Kobayashi, H.; Watanabe, R.; Choyke, P. L. Improving conventional enhanced permeability and retention (EPR) Effects; what is the appropriate target? Theranostics 2014, 4 (1) 81-89 10.7150/thno.7193
75. Owens, D. E., III; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 2006, 307 (1) 93-102 10.1016/j.ijpharm.2005.10.010
76. Venditto, V. J.; Regino, C. A. S.; Brechbiel, M. W. PAMAM dendrimer based macromolecules as improved contrast agents Mol. Pharmaceutics 2005, 2 (4) 302-311 10.1021/mp050019e
77. Nigavekar, S. S.; Sung, L. Y.; Llanes, M.; El-Jawahri, A.; Lawrence, T. S.; Becker, C. W.; Balogh, L.; Khan, M. K. 3H dendrimer nanoparticle organ/tumor distribution Pharm. Res. 2004, 21 (3) 476-483 10.1023/B:PHAM.0000019302.26097.cc
78. Pearson, R. M.; Juettner, V. V.; Hong, S. Biomolecular corona on nanoparticles: a survey of recent literature and its implications in targeted drug delivery Front. Chem. 2014, 10.3389/fchem.2014.00108
79. Åkesson, A.; Cárdenas, M.; Elia, G.; Monopoli, M. P.; Dawson, K. A. The protein corona of dendrimers: PAMAM binds and activates complement proteins in human plasma in a generation dependent manner RSC Adv. 2012, 2 (30) 11245-11248 10.1039/c2ra21866f